Lantheus Holdings, Inc.
LNTH
Classement en actions
#2853
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the... Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
Prix de l'action
$100.12
Capitalisation boursière
$6.54B
Changement (1 jour)
0.20%
Changement (1 an)
76.89%
Pays
US
Échange Lantheus Holdings, Inc. (LNTH)
Catégorie
Healthcare
Ratio P/E pour Lantheus Holdings, Inc. (LNTH)
Ratio P/E au October 2026 TTM : 23.75
Selon les derniers rapports financiers et le cours de l'action de Lantheus Holdings, Inc., le ratio P/E actuel (TTM) est de 23.75. À la fin de l’année 2023, le P/E de l’entreprise était de 12.96.
Historique du ratio P/E pour Lantheus Holdings, Inc. de 2011 à 2026
Ratio P/E à la fin de chaque année
| Année | Ratio P/E | Changez |
|---|---|---|
| 2026 (TTM) | 23.75 | 19.90% |
| 2024 | 19.81 | 52.92% |
| 2023 | 12.96 | -89.58% |
| 2022 | 124.35 | -554.61% |
| 2021 | -27.35 | -49.54% |
| 2020 | -54.20 | -314.65% |
| 2019 | 25.25 | 71.00% |
| 2018 | 14.77 | 139.02% |
| 2017 | 6.18 | -40.00% |
| 2016 | 10.30 | -283.82% |
| 2015 | -5.60 | -83.45% |
| 2014 | -33.85 | 1,602.20% |
| 2013 | -1.99 | -30.67% |
| 2012 | -2.87 | 222.49% |
| 2011 | -0.89 | 0.00% |
Ratio P/E pour des entreprises similaires ou concurrentes
| Entreprise | P/E Ratio | Différence du P/E Ratio | Pays |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 34.96 | 47.18% |
IN
|
Comment lire un P/E ratio ?
Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.
Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.
Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.